Report : Middle East & Africa Genotyping Market Forecast to 2031 – Regional Analysis – by Product Type (Instruments, Reagents and Kits, Bioinformatics, and Genotyping Services), Technology (Microarray, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption / MALDI-TOF, and Other Technologies), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, and Other Applications), and End user (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, and Other End Users)
At 17.0% CAGR, Middle East & Africa Genotyping Market is Projected to be Worth US$ 4,275.51 Million by 2031, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa genotyping market was valued at US$ 1,218.66 million in 2023 and is anticipated to reach US$ 4,275.51 million by 2031, recording a CAGR of 17.0% from 2023 to 2031. Use in diagnosis of genetic and rare diseases and expanding range of applications loss are among the critical factors attributed to drive the Middle East & Africa genotyping market growth.
According to the World Health Organization (WHO), ~35 million new cancer cases are likely to occur in 2050, a 77% increase from the corresponding 20 million cases in 2022.
Since cancer, Alzheimer’s disease, and rare diseases are difficult to identify clinically, genotyping stands as the backbone of diagnostic testing in the population. DNA sequences obtained from genotyping can be compared to sample or reference sequences to determine variations. Genotyping is also employed to detect single-nucleotide polymorphisms (SNPs), which are minor variations in genetic complement within the population. The human genome has nearly 660 million SNPs, which makes them the most widespread genetic variation. Moreover, by comparing polymorphisms in healthy and diseased populations, genome-wide association studies (GWAS) can uncover links between common illnesses and SNPs. GWAS can untangle the molecular mechanisms in underlying disease states by finding probable causes. SNPs are even present in single-celled organisms, such as bacteria. SNP genotyping can discriminate between microorganism isolates and could even be accustomed to identifying antibiotic-resistant strains. SNP-based strain detection has a significant impact on each pharmaceutical and clinical analysis, and it has also been used in infectious disease epidemiology.
Thus, the use of genotyping techniques in the diagnosis of genetic and rare diseases bolsters the genotyping market.
On the contrary, high cost of equipment and shortage of skilled professionals hamper the growth of Middle East & Africa genotyping market.
Based on product type, the Middle East & Africa genotyping market is categorized into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held 43.0% market share in 2023, amassing US$ 524.19 million. It is projected to garner US$ 1,938.39 million by 2031 to register 17.8% CAGR during 2023–2031.
By technology, the Middle East & Africa genotyping market is categorized into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held 33.7% share of Middle East & Africa genotyping market in 2023, amassing US$ 411.22 million. It is projected to garner US$ 1,394.64 million by 2031 to expand at 16.5% CAGR from 2023 to 2031.
Based on application, the Middle East & Africa genotyping market is categorized into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held 36.5% share of Middle East & Africa genotyping market in 2023, amassing US$ 444.74 million. It is predicted to garner US$ 1,731.08 million by 2031 to expand at 18.5% CAGR between 2023 and 2031.
By end user, the Middle East & Africa genotyping market is categorized into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held 60.3% share of Middle East & Africa genotyping market in 2023, amassing US$ 735.43 million. It is estimated to garner US$ 2,856.04 million by 2031 to expand at 18.5% CAGR during 2023–2031.
Based on country, the Middle East & Africa genotyping market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 35.9% share of Middle East & Africa genotyping market in 2023. It was assessed at US$ 437.88 million in 2023 and is likely to hit US$ 1,639.20 million by 2031, registering a CAGR of 17.9% during 2023–2031.
Key players operating in the Middle East & Africa genotyping market are Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA., among others.
- In January 2023, GE completed the separation of its healthcare business, launching GE HealthCare Technologies Inc. GE remains on track to launch GE Aerospace and GE Vernova as independent, industry-leading, investment grade companies in early 2024.
- In May 2023, Standard BioTools Inc. launched NGS library preparation functionality on the X9 High-Throughput Genomics System. For the first time ever, customers can perform real-time PCR and next-generation sequencing (NGS) library prep applications on a single benchtop system to support discovery through screening.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com